Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Regeneron Pharmaceuticals (REGN) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Regeneron Pharmaceuticals is one of 1048 companies in the Medical group. The Medical group currently sits at #16 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. REGN is currently sporting a Zacks Rank of #1 (Strong Buy).Over the past three months, the Zacks Consensus Estimate for REGN's full-year earnings has moved 1.99% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.Based on the latest available data, REGN has gained about 21.55% so far this year. Meanwhile, the Medical sector has returned an average of -2.27% on a year-to-date basis. This means that Regeneron Pharmaceuticals is outperforming the sector as a whole this year.Looking more specifically, REGN belongs to the Medical - Biomedical and Genetics industry, which includes 478 individual stocks and currently sits at #197 in the Zacks Industry Rank. Stocks in this group have lost about 0.72% so far this year, so REGN is performing better this group in terms of year-to-date returns.Going forward, investors interested in Medical stocks should continue to pay close attention to REGN as it looks to continue its solid performance. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here.